Uniqure NV (QURE NASDAQ) stock market data APIs
$21.1704
-1.08(-5.1%)
as of May 5, 2026
Try our APIs with
free plan!
Uniqure NV Financial Data Overview
Price chart is built with
Anychart
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prev. Close
21.1704
Open
20.0901
High
21.2424
Low
19.596
52 wk Range
8.73-71.5
Market Cap
1 304 M
Shares Outstanding
63 033 K
Revenue
16 098 K
EPS
-0.4739
Beta
0.869
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Uniqure NV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Uniqure NV data using free add-ons & libraries
Get Uniqure NV Fundamental Data
Uniqure NV Fundamental data includes:
- Net Revenue: 16 098 K
- EBITDA: -164 343 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-02
- EPS/Forecast: -0.9168
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Uniqure NV News
New
UniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029
Earnings Call Insights: uniQure N.V. (QURE) Q1 2026 MANAGEMENT VIEW * "During the first quarter of 2026, uniQure remained focused on advancing AMT-130 to patients" and, following the January Type ...
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on tr...
Here are the major earnings before the open Tuesday
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * Energy Transfe...
Sector Update: Health Care Stocks Gain Late Afternoon
Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get Uniqure NV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
